AUTHORS

Real Money authors - Stephen Guilfoyle

Stephen Guilfoyle

Stephen "Sarge" Guilfoyle is the founder and President of Sarge986 LLC, a family run trading operation. An NYSE floor trader for over 30 years, Guilfoyle has served as the Chief Market Economist for Stuart Frankel & Co., the U.S. Economist for Meridian Equity Partners, and as a Vice President in Block Trading and Investment Banking with Credit Suisse over the years. Guilfoyle earned his nickname serving as an actual sergeant in reserve components of the US Marine Corps, and US Army while simultaneously working on Wall Street.
Email Stephen Guilfoyle

Recent Articles By The Author

Oil Attack's Ripple Effects and the Case for Defense Stocks: Market Recon

The drone attacks on Saudi oil operations even could influence the Fed's thinking on inflation and rates.

Food for Thought on How I'd Trade Broadcom

Their fiscal third quarter earnings results gave investors reason to pause.

Market Faces Stiff Resistance, China Issues, Trading ZTO Express: Market Recon

There is no denying that markets got ugly over the last 30 minutes or so of the Thursday session.

CVS Must Be Taking Some of Its Own Medicine: It Appears in Great Shape

Following its Aetna acquisition that closed back in November, CVS is positioning itself for further strength.

Small-Caps Are Hot, Playing Ball With China, Trading Nvidia: Market Recon

The bond market is running the show? The answer would be... as much if not more than anything else... again.

Attention Grabbers for Apple: The Series 5 Watch and Streaming Services

Apple is taking the necessary steps in order to set up future success ahead of the advent of 5G technology.

Thick Skin for These Markets, Saudi Aramco IPO, Trading Zscaler: Market Recon

A market repricing...which are the 'true' growth stocks now?

Own AT&T? Verizon Has a Better Dividend, Better Focus

Elliott Management has expressed concern over not just the expense made in diversifying AT&T's overall business direction, but also in the reshuffling of leadership at the C-level.

Value vs. Growth, ECB vs. FOMC, Dividend Stocks, Positive on Apple: Market Recon

Should competitors act in a way that puts the U.S. economy at a disadvantage, then by all means the FOMC must act with a level of anger that intimidates.

Could Small Drug Trial Hold Big Potential for Amgen?

The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight